Data in Biotech Decoding the Dark Proteome: Biological Insights for Pharma with Dr. Jonathan Usuka from Sapient
10 snips
Apr 2, 2025 Dr. Jonathan Usuka, CEO of Sapient and expert in bioinformatics, dives into the transformative world of proteomics and metabolomics. He breaks down the complexities of the dark proteome and how understanding these uncharacterized proteins can enhance drug discovery. The conversation highlights the need for longitudinal patient sampling and robust conclusions for biopharma. Usuka also discusses the FDA's evolving perspective on real-world data, crucial for advancing personalized medicine and patient care in biotechnology.
AI Snips
Chapters
Transcript
Episode notes
Usuka's Journey
- Jonathan Usuka's background is in bioinformatics and genomics.
- He founded a genomics company acquired by Roche, worked at McKinsey, and now leads Sapient.
Sapient's Mission
- Sapient performs deep molecular characterizations of diseases from patient samples.
- This helps pharmaceutical companies discover and advance therapies, optimizing patient response.
Real-World Data vs. Clinical Trials
- Real-world data offers larger sample sizes and reflects real treatment contexts, unlike controlled clinical trials.
- However, it often lacks depth in patient outcomes and mainly tracks transactions.